Welcome to our dedicated page for GENTEX SEC filings (Ticker: GNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gentex Corporation's SEC filings document recurring financial-reporting, governance and capital-allocation disclosures for an operating technology supplier. Recent Form 8-K reports furnish quarterly and annual earnings releases, including net sales, margins, operating income, share repurchases, and separate references to core Gentex results and VOXX contributions after the completed acquisition.
Proxy materials cover board elections, shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filing record frames Gentex's public-company reporting around its digital vision, connected car, dimmable glass, fire protection, medical device and consumer electronics businesses.
Gentex Corporation is reported as having a significant shareholder group consisting of American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research. These reporting persons collectively report beneficial ownership of 11,025,677 shares of Gentex common stock, representing 5.2% of the outstanding class as of June 30, 2026.
They report sole voting powersole dispositive power
Gentex Corporation reported Q2 2026 net sales of $651,299,705, down 1% from Q2 2025, while net income attributable to Gentex rose to $114,689,417 and diluted EPS to $0.54 from $0.43. Consolidated gross margin improved to 37.0%, helped by approximately $18 million of IEEPA tariff reimbursements and favorable product mix, partly offset by commodity cost increases and lower automotive volumes.
For the six months ended June 30, 2026, net sales were $1,326,742,831 and net income attributable to Gentex was $213,144,560, with diluted EPS of $1.00. Operating cash flow reached $321,663,680, supporting $137,873,659 of share repurchases, $51,409,775 of dividends, and $36,237,437 of capital spending. Cash and cash equivalents were $233,444,229 with no borrowings under the $350 million revolving credit facility and $3,706,980 of short-term debt.
Automotive Products remained the largest segment with Q2 sales of $560,201,415 and a 10% decline in total auto-dimming mirror units to 10,416 thousand, driven by weaker international interiors. Premium Audio Products revenue increased to $51,687,407 and Other segment revenue to $39,410,883, reflecting contributions from the 2025 VOXX and BioConnect acquisitions. Year‑to‑date results include a $2.8 million impairment of Vaporsens in‑process R&D, $12.2 million of impairments on two technology investments, and a $5.1 million increase in credit loss allowances on loans to technology investees.
Gentex Corporation reported second-quarter 2026 net sales of $651.3 million, a 1% decrease from a year earlier, while expanding gross margin to 37.0% from 34.2%. GAAP income from operations rose to $141.3 million and net income attributable to Gentex increased 19% to $114.7 million. Diluted EPS was $0.54, with adjusted diluted EPS of $0.58. Automotive net sales were $560.1 million, down from $578.1 million, while Premium Audio grew to $51.7 million and Other Products to $39.4 million. Total auto-dimming mirror units shipped declined 10% to 10,416 thousand, including a 26% drop in international interior mirrors.
The company repurchased 2.7 million shares for $66.0 million in the quarter and 5.9 million shares for $137.6 million year-to-date, with 29.9 million shares still available under its plan. For 2026, Gentex guides consolidated revenue to $2.65–$2.75 billion, gross margin of 34.5%–35.5%, operating expenses of $405–$415 million, a tax rate of 16%–17%, and capital expenditures of $115–$125 million. For 2027, it continues to expect revenue between $2.80 and $2.90 billion, against a backdrop of slightly declining global light vehicle production in 2026 and flat levels in 2027.
Gentex Corporation reported the results of its 2026 annual shareholder meeting, where all director nominees were elected to one-year terms expiring in 2027. Support for most nominees was strong, with several receiving over 171 million votes for and broker non-votes totaling 17,860,451 on each director item.
Shareholders also ratified Ernst & Young LLP as auditors for the fiscal year ending December 31, 2026, with 183,982,692 votes for, 6,360,110 against, and 158,329 abstentions. In an advisory vote, shareholders approved the compensation of the named executive officers, receiving 167,822,852 votes for, 4,448,682 against, 369,146 abstentions, and 17,860,451 broker non-votes.
In addition, shareholders approved the Gentex Corporation 2026 Omnibus Incentive Plan, with 149,753,126 votes for, 22,571,717 against, 315,837 abstentions, and 17,860,451 broker non-votes, confirming continued authorization for equity-based and other incentives under the new plan.
KENNEDY JOHN C reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director John C. Kennedy reported an equity award of 5,626 shares of Common Stock. The shares were granted at no cash cost to him as a compensation award and will vest 100% one year from the grant date. Following this grant, he holds 5,626 shares directly.
GENTEX CORP director John C. Kennedy has filed an initial insider ownership report on Form 3. The filing lists his position in the company’s Common Stock as zero shares following the reported date of May 21, 2026, and shows no buy or sell transactions.
Zang Ling reported acquisition or exercise transactions in this Form 4 filing.
Gentex Corp director Ling Zang reported an equity award of 5,626 shares of Common Stock. The shares were granted at no cost as a compensation award and will vest 100% one year from the grant date. Following this grant, Zang directly holds 35,599 Gentex shares.
WALKER BRIAN C reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Brian C. Walker received a stock award of 5,626 shares of common stock as equity compensation. The shares were granted at no cash cost and will vest 100% one year from the grant award date. Following this award, Walker directly holds 29,831 common shares.
Starkoff Kathleen reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Kathleen Starkoff reported receiving a stock award of 5,626 shares of Common Stock as a compensation-related grant. The shares were awarded at no cash cost and increase her direct holdings to 36,770 shares following the transaction. According to the disclosure, the entire award vests 100% one year from the grant award date, meaning she will gain full ownership after the one-year vesting period.
GENTEX CORP director Richard O. Schaum reported an equity award of 5,626 shares of Common Stock, received at a price of $0.00 per share as a grant or award acquisition. These shares vest 100% one year from the grant award date. Following this transaction, Schaum directly holds 87,069 shares.